Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 4
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
An assessment of patient perspectives on pharmacogenomics educational materials.
Asiedu GB, Finney Rutten LJ, Agunwamba A, Bielinski SJ, St Sauver JL, Olson JE, Rohrer Vitek CR. Asiedu GB, et al. Pharmacogenomics. 2020 Apr;21(5):347-358. doi: 10.2217/pgs-2019-0175. Epub 2020 Apr 15. Pharmacogenomics. 2020. PMID: 32292118 Free PMC article.
Aim: Pharmacogenomics (PGx) holds potential to improve patient treatment; yet, effective patient educational materials are limited. ...Recommendations were to enhance comprehension and utility and to customize materials to each patient
Aim: Pharmacogenomics (PGx) holds potential to improve patient treatment; yet, effective patient educational
Biocompatibility of Materials for Biomedical Engineering.
Tyan YC, Yang MH, Chang CC, Chung TW. Tyan YC, et al. Adv Exp Med Biol. 2020;1250:125-140. doi: 10.1007/978-981-15-3262-7_9. Adv Exp Med Biol. 2020. PMID: 32601942 Review.
Tissue engineering is a well-investigated and challenging biomedical field, with promising perspectives to improve and support quality of life for the patient. To assess the response of those extracellular matrices (ECMs), induced by biomedical materials
Tissue engineering is a well-investigated and challenging biomedical field, with promising perspectives to improve and support qualit …
DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice.
Martens FK, Huntjens DW, Rigter T, Bartels M, Bet PM, Cornel MC. Martens FK, et al. Front Pharmacol. 2020 Jan 28;10:1609. doi: 10.3389/fphar.2019.01609. eCollection 2019. Front Pharmacol. 2020. PMID: 32047438 Free PMC article.
Pretreatment DPYD genotyping identifies approximately 50% of the patients that will develop severe FP toxicity. The aim of the study was to assess the uptake of DPD testing in the Amsterdam University Medical Centers over time and to evaluate stakeholder experiences …
Pretreatment DPYD genotyping identifies approximately 50% of the patients that will develop severe FP toxicity. The aim of the study …
Drug Attitude, Insight, and Patient's Knowledge About Prescribed Antipsychotics in Schizophrenia: A Cross-Sectional Survey.
Nagai N, Tani H, Yoshida K, Gerretsen P, Suzuki T, Ikai-Tani S, Mimura M, Uchida H. Nagai N, et al. Neuropsychiatr Dis Treat. 2020 Mar 23;16:781-787. doi: 10.2147/NDT.S240377. eCollection 2020. Neuropsychiatr Dis Treat. 2020. PMID: 32256074 Free PMC article.
INTRODUCTION: While patients' perspectives toward pharmacotherapy are expected to be directly influenced by their motivation and understanding of the treatment that they are currently receiving, no study has comprehensively investigated the impact of insight into il …
INTRODUCTION: While patients' perspectives toward pharmacotherapy are expected to be directly influenced by their motivation a …
Providers' perspectives on the clinical utility of pharmacogenomic testing in pediatric patients.
Liko I, Lee YM, Stutzman DL, Blackmer AB, Deininger KM, Reynolds AM, Aquilante CL. Liko I, et al. Pharmacogenomics. 2021 Apr;22(5):263-274. doi: 10.2217/pgs-2020-0112. Epub 2021 Mar 4. Pharmacogenomics. 2021. PMID: 33657875
Aim: To assess providers' knowledge, attitudes, perceptions, and experiences related to pharmacogenomic (PGx) testing in pediatric patients. Materials & methods: An electronic survey was sent to multidisciplinary healthcare providers at a pediatric …
Aim: To assess providers' knowledge, attitudes, perceptions, and experiences related to pharmacogenomic (PGx) testing in pedia …